AVTR vs WAT
AVTR: A global provider of mission-critical products and services for laboratory research and production workflows across biopharma and advanced industries. WAT: A leading global analytical instruments and life sciences company combining chromatography, mass spectrometry, and diagnostic solutions following a transformative $16.8 billion acquisition of BD's biosciences and diagnostics businesses.
Side-by-side fundamentals
| Metric | AVTR | WAT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $13.78 | $371.20 | |
| Market cap as of 2026-08-03 | $9.4B | $36.4B | |
| P/E as of 2026-08-03 | n/a | 83.12 | |
| Net margin as of 2026-08-03 | -8.4% | +11.9% | WAT higher |
| Gross margin as of 2026-08-03 | +32.1% | +55.1% | WAT higher |
| Operating margin as of 2026-08-03 | -4.6% | +16.0% | WAT higher |
| ROE as of 2026-08-03 | -9.6% | +8.0% | WAT higher |
| ROA as of 2026-08-03 | -4.6% | +4.6% | WAT higher |
| Debt / equity as of 2026-08-03 | 0.68 | 0.34 | WAT lower |
| Revenue growth (YoY) as of 2026-08-03 | -2.0% | +26.4% | WAT higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | +2.1% | WAT higher |
| Beta as of 2026-08-03 | 0.98 | 1.19 | |
| 1-year return as of 2026-07-31 close | +2.5% | +22.5% | WAT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.